Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...
Business Wire14h
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via ...
PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...
CRISPR upgraded to hold by TD Cowen on limited downside
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...
Seaport's Glyph platform shows 55% drug absorption in lymphatics
BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company, has published new research demonstrating significant advancements in drug delivery through the lymphatic system using its ...
Crispr Therapeutics price target raised to $120 from $100 at Truist
Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...
CRISPR stock rating raised to hold by TD Cowen, target steady
CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...